Haeussler Katrin, Wang Xuan, Winfree Katherine B, D'yachkova Yulia, Traore Sory, Puri Tarun, Thom Howard, Papagiannopoulos Christos, Nassim Maria, Taipale Kaisa
ICON plc, Munich, 81829, Germany.
ICON plc, Stockholm, 111 21, Sweden.
Future Oncol. 2022 May;18(16):2007-2028. doi: 10.2217/fon-2021-0885. Epub 2022 Feb 21.
To evaluate the comparative efficacy and safety of identified first-line therapies for patients with mutation-positive (m+) advanced non-small-cell lung cancer (NSCLC), with a focus on ramucirumab + erlotinib. In the absence of head-to-head studies, a Bayesian network meta-analysis was conducted using randomized clinical trial data to evaluate first-line systemic therapies with erlotinib/gefitinib as the reference treatment. For progression-free survival, ramucirumab + erlotinib was comparable to osimertinib and dacomitinib in the primary analysis. The analysis showed ramucirumab + erlotinib efficacy to be comparable to best-in-class treatment options for previously untreated patients with m advanced NSCLC. PROSPERO ID: CRD42020136247.
为评估已确定的一线疗法对突变阳性（m+）晚期非小细胞肺癌（NSCLC）患者的比较疗效和安全性，重点关注雷莫西尤单抗+厄洛替尼。在缺乏头对头研究的情况下，使用随机临床试验数据进行了贝叶斯网络荟萃分析，以评估以厄洛替尼/吉非替尼作为对照治疗的一线全身疗法。对于无进展生存期，在初步分析中，雷莫西尤单抗+厄洛替尼与奥希替尼和达可替尼相当。分析表明，雷莫西尤单抗+厄洛替尼的疗效与之前未接受治疗的m晚期NSCLC患者的同类最佳治疗方案相当。PROSPERO编号：CRD42020136247。
